gsk201410206k3.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending October 2014
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--



 
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
I give below details of the following increases in interests in Ordinary Shares in GlaxoSmithKline plc purchased at a price of 1411.09 pence per Share on 3 October 2014, in respect of the personal holdings of the under-mentioned persons following the re-investment of the dividend paid to shareholders on 2 October 2014.
 
 
 
 
Ordinary Shares
Sir Andrew Witty
 
1434.057
Mr R G Connor
 
91.016
Mr S Dingemans
 
662.544
Mr S A Hussain
 
1818.946
Mr D S Redfern
 
666.527
Dr M M Slaoui
 
148.779
Ms C Thomas
 
812.376
Mr P C Thomson
 
262.941
Dr P J T Vallance
 
917.784
Ms E Walmsley
 
744.535
 
 
The Company was advised of this information on 17 October 2014.
 
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
 
 
V A Whyte
Company Secretary
 
20 October 2014
 
 

 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: October 20, 2014 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc